What's Going On With Pfizer Shares Wednesday?
What's Going On With Pfizer Shares Wednesday?
Pfizer Inc. (NYSE:PFE) is experiencing notable stock movement on Wednesday afternoon. Here's what you need to know.
輝瑞公司（紐交所：PFE）週三下午遭遇顯着的股票波動。以下是您需要了解的情況。
What's Going On: Pfizer is actively engaged in an open-label extension (OLE) study to evaluate the safety and efficacy of etrasimod in patients with moderately to severely active ulcerative colitis (UC). This study is an extension of previous Phase 2 and Phase 3 double-blind, placebo-controlled studies.
發生了什麼：輝瑞正在積極開展一項開放標籤擴展（OLE）研究，評估etrasimod治療中度至重度活動性潰瘍性結腸炎（UC）患者的安全性和療效。此研究是上一階段2和3期雙盲安慰劑對照研究的延期。
The OLE study is designed to treat participants with etrasimod 2 mg tablets, administered orally once daily for up to approximately eight years or until marketing authorization is obtained in the participant's country, whichever comes first.
OLE研究旨在用etrasimod 2毫克片劑治療參與者，一天一次口服，給藥時間長達8年，或在參與者所在國獲得上市授權之前，以先到者爲準。
The primary objective of the study is to assess safety by evaluating adverse events over the study period. Secondary outcome measures include the proportion of participants achieving clinical remission and changes from baseline in total and partial Mayo scores, which are tools designed to measure disease activity in ulcerative colitis.
該研究的主要目標是通過評估研究期間的不良事件來評估安全性。次要結果指標包括實現臨床緩解的參與者比例以及總馬約評分和部分馬約評分的改變，這些工具旨在測量潰瘍性結腸炎的疾病活動度。
What Else: Additional outcomes will look at endoscopic improvement, clinical response and histologic improvement and remission, assessed by various histopathology scores.
其他結果將觀察內窺鏡改善，臨床反應和組織學改善和緩解，通過各種組織病理評分進行評估。
Pfizer recently reported a 15% decrease in patient enrollment in its Phase 3 ulcerative colitis trial, with numbers dropping from 912 to 772 patients. The trial remains active but is not recruiting new participants. Consequently, the primary completion date has been revised to July 20, 2026.
輝瑞最近報告其3期潰瘍性結腸炎試驗患者註冊人數減少了15％，從912名患者減少到772名患者。該試驗仍在進行中，但不再招募新參與者。因此，主要完成日期已修訂爲2026年7月20日。
Analyst Update: Cantor Fitzgerald's analyst Louise Chen maintains an optimistic outlook on Pfizer, reiterating an "Overweight" rating with a $45 price target.
分析師更新：康泰納菲的分析師路易絲·陳（Louise Chen）對輝瑞持樂觀態度，重申“增持”評級，並給出45美元的目標價格。
PFE Price Action: Pfizer shares were down by 2.09% at $27.41 at the time of writing, according to Benzinga Pro.
PFE價格行動：根據Benzinga Pro的數據，在撰寫本文時，輝瑞股價下跌2.09％至27.41美元。
Photo via Shutterstock.
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。